Factors behind the Increase in Cardiovascular Mortality in Russia: Apolipoprotein AI and B Distribution in the Arkhangelsk Study 2000

Clinical Chemistry

Volumn 50, Issue 2, 2004, Pages 346-354

  Averina, Maria ^a   Nilssen, Odd ^a   Brenn, Tormod ^a   Brox, Jan ^b   Arkhipovsky, Vadim L ^c   Kalinin, Alexei G ^d  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c Semashko Clinic   (Russian Federation)

^d NORTHERN STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B;

ADULT; AGE DISTRIBUTION; AGED; ALCOHOL CONSUMPTION; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; RUSSIAN FEDERATION; SELF REPORT; SEX RATIO; WORLD HEALTH ORGANIZATION;

ADULT; ALCOHOL DRINKING; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; RUSSIA; SEX FACTORS; SMOKING;

EID: 0742287011     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2003.023853     Document Type: Article

References (46)

1. Notzon FC, Komarov YM, Ermakov SP, Sempos CT, Marks JS, Sempos EV. Causes of declining life expectancy in Russia. JAMA 1998;279:793-800.
2. Goskomstat of Russia. Information about social and economic condition in Russia. January-April 2003 [Russian]. http://www. gks.ru/bd-1.asp (Accessed June 2003).
3. Averina M, Nilssen O, Brenn T, Brox J, Kalinin AG, Arkhipovsky VL. High cardiovascular mortality in Russia cannot be explained by the classical risk factors. The Arkhangelsk Study 2000. Eur J Epidemiol 2003;18:871-8.
4. Ginter E. Cardiovascular risk factors in the former communist countries. Analysis of 40 European MONICA populations. Eur J Epidemiol 1995;11:199-205.
5. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, Fortmann S, Sans S, Tolonen H, et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA project populations. Lancet 2000;355:675-87.
6. Perova NV, Oganov RG, Williams DH, Irving SH, Abernathy JR, Deev AD, et al. Association of high density lipoprotein cholesterol with mortality and other risk factors for major chronic non-communicable diseases in samples of US and Russian men. Ann Epidemiol 1995;5:179-85.
7. Durrington PN, Ishola M, Hunt L, Arrol S, Bhatnagar D. Apolipoproteins (a), AI, and B and parental history in men with early onset ischemic heart disease. Lancet 1988;1:1070-3.
8. Salonen JT, Salonen R, Penttilä I, Herranen J, Jauhiainen M, Kantola M, et al. Serum fatty acids, apolipoproteins, selenium and vitamin antioxidants and the risk of death from coronary artery disease. Am J Cardiol 1985;56:226-31.
9. Kwiterovich PO, Coresh J, Smith HH, Bachorik PS, Derby CA, Pearson TA. Comparison of the plasma levels of apolipoproteins B and AI, and other risk factors in men and women with premature coronary artery disease. Am J Cardiol 1992;69:1015-21.
10. Sedlis SP, Schechtman KB, Ludbrook PA, Sobel BE, Schonfeld G. Plasma apoproteins and the severity of coronary artery disease. Circulation 1986;73:978-86.
11. Riesen WF, Mordasini R, Salzmann C, Theler A, Gurtner HP. Apoproteins and lipids as discriminators of severity of coronary heart disease. Atherosclerosis 1980;37:157-62.
12. Francis MC, Frohlich JJ. Coronary artery disease in patients at low risk-apolipoprotein AI as an independent risk factor. Atherosclerosis 2001;155:165-70.
13. Lamarche B, Moorjani S, Lupien P, Cantin B, Bernard P-M, Dagenais GR, et al. Apolipoprotein AI and B levels and the risk of ischemic heart disease during a 5-year follow-up of men in the Quebec cardiovascular study. Circulation 1996;94:273-8.
14. Klausen IC, Sjøl A, Hansen PS, Gerdes LU, Møller L, Lemming L, et al. Apolipoprotein(a) isoforms and coronary heart disease in men. Atherosclerosis 1997;132:77-84.
15. Sigurdsson G, Baldursdottir A, Sigvaldason H, Agnarsson U, Thorgeirsson G, Sigfusson N. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol 1992;69:1251-4.
16. Wald NJ, Law M, Watt HC, Wu T, Bailey A, Johnson AM, et al. Apolipoproteins and ischemic heart disease: implications for screening. Lancet 1994;343:75-9.
17. Aasvee K, Jauhiainen M, Kurvinen E, Jordania R, Sundvall J, Ehnholm C. Lipoprotein (a), apolipoprotein AI and B serum levels in young families from Tallinn, Estonia. Relationships with other cardiovascular risk factors and nationality. Scand J Clin Lab Invest 1999;59:179-89.
18. Goskomstat of the Russia. Women and men of the Arkhangelsk region: statistic compendium [Russian]. Arkhangelsk, Russia: Arkhangelsk Region Committee of State Statistics, 2000.
19. Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins AI and B. IV. Comparability of apolipoprotein B values by use of International Reference Material. Clin Chem 1994;40:586-92.
20. Marcovina SM, Albers JJ, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins AI and B. III. Comparability of apolipoprotein AI values by use of International Reference Material. Clin Chem 1993;39:773-81.
21. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment panel II). NIH Publication No 93-3096. Bethesda, MD: NIH, September 1993.
22. Dilorio F, Hardy KA. Quick start to data analysis with SAS. Belmont, CA: Wadsworth Publishing Company, 1996.
23. The 6th analytical report about demographic situation in Russia. Center of Demography and Human Ecology, 1999 [Russian]. http://www.demoscope.ru/dem-98/ sod-r.html (Accessed June 2003).
24. Bachorik PS, Lovejoy KL, Carrol MD, Johnson CL. Apolipoprotein B and AI distributions in the United States, 1988-1991: results of the National Health and Nutrition Examination Survey III (NHANES III). Clin Chem 1997;43:2364-78.
25. Contois JH, McNamara JR, Lammi-Keefe CJ, Wilson PWF, Massov T, Schaefer EJ. Reference intervals for plasma apolipoprotein AI determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clin Chem 1996;42:507-14.
26. Contois JH, McNamara JR, Lammi-Keefe CJ, Wilson PWF, Massov T, Schaefer EJ. Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clin Chem 1996;42:515-23.
27. Leino A, Impivaara O, Kaitsaari M, Järvisalo J. Serum concentrations of apolipoprotein AI, apolipoprotein B and lipoprotein(a) in a population sample. Clin Chem 1995;41:1633-6.
28. Goskomstat of Russia. Information about social and economic condition in Russia. January-December 2001 [Russian]. http:// www.gks.ru/bd_fa.asp (Accessed June 2003).
29. Albers JJ, Cheung MC, Wahl PW. Effect of storage on the measurement of apolipoproteins AI and All by radial immunodiffusion. J Lipid Res 1980;21:874-8.
30. Camargo CAJ, Williams PT, Vranizan KM, Albers JJ, Wood PD. The effect of moderate alcohol intake on serum apolipoproteins AI and All. A controlled study. JAMA 1985;253:2854-7.
31. 3 cholesterol. Atherosclerosis 2000;152:503-10.
32. De Oliveira e Silva ER, Foster D, McGee Harper M, Seidman CE, Smith JD, Breslow JL, et al. Alcohol consumption raises HDL cholesterol levels by increasing the transport rate of apolipoproteins AI and All. Circulation 2000;102:2347-52.
33. Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ 1999; 319:1523-8.
34. Rakic V, Puddley IB, Dimmitt SB, Burke V, Beilin LJ. A controlled trial of the effects of pattern of alcohol intake on serum lipid levels in regular drinkers. Atherosclerosis 1998;137:243-52.
35. Nilssen O, Førde OH. The Tromsø Study: the positive predictive value of gamma-glutamyltransferase and an alcohol questionnaire in the detection of early-stage drinkers. J Intern Med 1991;229: 497-500.
36. Lee D-H, Jakobs DR, Gross M, Kiefe CI, Roseman J, Lewis CE, et al. γ-Glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Clin Chem 2003;49:1358-66.
37. Bots ML, Salonen JT, Elwood PC, Nikitin Y, de Concalves AF, Inzitari D, et al. γ-Glutamyltransferase and risk of stroke: the EUROSTROKE project. J Epidemiol Community Health 2002;56: 125-9.
38. Høyer G, Nilssen O, Brenn T, Schirmer H. The Svalbard Study 1988-89: a unique setting for validation of self-reported alcohol consumption. Addiction 1995;90:539-44.
39. World Health Organization. Global status report on alcohol, 1999. http://www.who.int/substance_abuse/pubs_alcohol.htm (Accessed June 2003).
40. Wannamethee G, Shaper AG. Alcohol and sudden cardiac death. Br Heart J 1992;68:443-8.
41. Kauhanen J, Kaplan GA, Goldberg DE, Salonen JT. Beer binging and mortality: results from the Kuopio Ischaemic Heart Disease Risk Factor Study, a prospective population based study. BMJ 1997;315:846-51.
42. Laatikainen T, Manninen L, Poikolainen K, Vartiainen E. Increased mortality related to heavy alcohol intake pattern. J Epidemiol Community Health 2003;57:379-84.
43. Malyutina S, Bobak M, Kurilovitch S, Gafarov V, Simonova G, Nikitin Y, et al. Relation between heavy and binge drinking and all-cause and cardiovascular mortality in Novosibirsk, Russia: a prospective cohort study. Lancet 2002;360:1448-54.
44. Leon DA, Chenet L, Shkolnikov VM, Zakharov S, Shapiro J, Rakhmanova G, et al. Huge variation in Russian mortality rates 1984-94: artefact, alcohol, or what? Lancet 1997;350:383-8.
45. Chenet L, McKee M, Leon D, Shkolnikov V, Vassin S. Alcohol and cardiovascular mortality in Moscow; new evidence of a causal association. J Epidemiol Community Health 1998;52:772-4.
46. Chenet L, Britton A, Kalediene R, Petrauskiene J. Daily variations in deaths in Lithuania: the possible contribution of binge drinking. Int J Epidemiol 2001;30:743-8.